News for Instil Bio, Inc. (TIL)

Does Instil Bio, Inc. (TIL) have what it takes to be a top stock pick for momentum investors? Let's find out.

**media[651576]**

Does Instil Bio, Inc. (TIL) have what it takes to be a top stock pick for momentum investors? Let's find out.

On June 2, 2025, analyst Reni Benjamin from JMP Securities reiterated a "Market Perform" rating for Instil Bio (TIL). The latest report suggests continued obser

Instil Bio, identified with the ticker TIL, has announced the hiring of Dr. Jamie Freedman as its new Chief Medical Officer. Dr. Freedman brings a wealth of exp

DALLAS, June 02, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (”œInstil”) ( TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline

Instil Bio (TIL) has announced the appointment of Jamie Freedman as Chief Medical Officer.  Jamie Freedman is a Hematologist-Oncologist and a highly experienced biopharmaceutical executive.

Instil Bio (TIL) to present at the Jefferies Global Healthcare Conference on June 5, 2025. CEO Bronson Crouch will deliver the presentation at 4:20 PM E

DALLAS, May 30, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ( TIL, "Instil"), a clinical-stage biopharmaceutical company focused on developing a pipeline of nov

**media[641260]**

Florida-based Zeo Energy Corp. (ZEO) is up over 121 percent in Thursday's pre-market trading. The following are some of the other stocks making big moves in Thursday's pre-market trading.

New York-based Eyenovia, Inc. (EYEN) is up over 52 percent in Tuesday's pre-market trading. The following are some of the other stocks making big moves in Tuesday's pre-market trading.

Clinical data for AXN-2510/IMM2510 monotherapy in relapsed/refractory NSCLC in China by ImmuneOnco, as well as additional safety data in other solid tumors, ant

**media[556689]**

Instil Bio shifts to bispecific immunotherapy with SYN-2510 for solid tumors.

**media[514491]**

Instil Bio is a clinical-stage biotech focusing on personalized immunotherapy. Check out my recommendation for TIL stock.

Instil Bio (TIL) reported Q3 2024 GAAP EPS of -$3.54.

**media[464680]**